Index -
P/E -
EPS (ttm) -0.86
Insider Own 27.55%
Shs Outstand 32.17M
Perf Week -4.23%
Market Cap 58.23M
Forward P/E -
EPS next Y -1.28
Insider Trans 0.06%
Shs Float 23.30M
Perf Month -11.27%
Income -25.79M
PEG -
EPS next Q -0.24
Inst Own 20.69%
Short Float 0.98%
Perf Quarter -4.23%
Sales 0.00M
P/S -
EPS this Y -17.83%
Inst Trans -0.79%
Short Ratio 1.08
Perf Half Y 35.07%
Book/sh 0.76
P/B 2.38
EPS next Y -26.64%
ROA -60.26%
Short Interest 0.23M
Perf Year -11.27%
Cash/sh 0.93
P/C 1.95
EPS next 5Y -
ROE -79.69%
52W Range 0.90 - 3.49
Perf YTD -2.16%
Dividend Est. -
P/FCF -
EPS past 5Y -21.09%
ROI -105.37%
52W High -48.14%
Beta 1.62
Dividend TTM -
Quick Ratio 3.37
Sales past 5Y 0.00%
Gross Margin -
52W Low 101.09%
ATR (14) 0.13
Dividend Ex-Date -
Current Ratio 3.37
EPS Y/Y TTM 3.78%
Oper. Margin 0.00%
RSI (14) 41.37
Volatility 5.88% 7.25%
Employees 28
Debt/Eq 0.01
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 7.00
Option/Short No / Yes
LT Debt/Eq 0.00
EPS Q/Q -48.01%
Payout -
Rel Volume 0.87
Prev Close 1.82
Sales Surprise -
EPS Surprise 15.62%
Sales Q/Q -
Earnings Mar 26 BMO
Avg Volume 210.69K
Price 1.81
SMA20 -5.06%
SMA50 -13.21%
SMA200 5.28%
Trades
Volume 156,023
Change -0.55%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-03-21 Initiated
Oppenheimer
Outperform
$22
Nov-03-21 Initiated
B. Riley Securities
Buy
$27
Mar-27-24 09:31AM
01:13AM
(Thomson Reuters StreetEvents)
Mar-26-24 11:53AM
07:00AM
Mar-15-24 07:30AM
04:05PM
Loading…
Mar-14-24 04:05PM
Mar-11-24 08:16PM
04:05PM
Mar-06-24 07:30AM
Feb-26-24 07:30AM
Feb-06-24 08:47AM
Jan-04-24 07:30AM
Nov-16-23 07:30AM
Nov-15-23 07:30AM
Nov-07-23 07:30AM
06:00AM
Loading…
Nov-03-23 06:00AM
Nov-02-23 07:30AM
Oct-27-23 07:30AM
Oct-24-23 04:30PM
Oct-16-23 07:30AM
Sep-07-23 07:45AM
Aug-30-23 08:00AM
Aug-09-23 09:09AM
Aug-08-23 09:52PM
(Thomson Reuters StreetEvents)
07:00AM
Aug-02-23 07:30AM
Jul-11-23 07:30AM
Jul-05-23 07:30AM
Jun-28-23 07:00AM
Jun-27-23 07:17PM
07:30AM
Loading…
Jun-20-23 07:30AM
Jun-02-23 07:30AM
May-23-23 09:40AM
07:30AM
May-18-23 03:53PM
07:30AM
May-04-23 04:05PM
May-01-23 07:30AM
Apr-19-23 07:30AM
Apr-12-23 07:30AM
Mar-28-23 07:30AM
Mar-27-23 08:00AM
07:12AM
Mar-23-23 11:03PM
(Thomson Reuters StreetEvents)
07:30AM
Mar-21-23 08:00AM
Mar-16-23 12:18PM
07:30AM
Mar-15-23 07:30AM
Mar-07-23 08:00AM
Feb-22-23 08:00AM
Feb-21-23 07:30AM
Feb-20-23 08:50AM
Feb-09-23 08:00AM
Dec-22-22 08:00AM
Dec-21-22 04:05PM
Dec-15-22 08:00AM
Dec-01-22 08:38AM
(Simply Wall St.) -25.93%
07:30AM
Nov-28-22 08:00AM
Nov-21-22 08:00AM
Nov-15-22 12:55PM
Nov-14-22 08:00AM
Nov-10-22 08:00AM
Oct-12-22 08:00AM
Oct-11-22 08:00AM
Sep-29-22 07:30AM
Sep-27-22 07:32AM
Sep-06-22 07:32AM
Aug-11-22 06:56AM
Aug-09-22 07:00AM
Aug-04-22 04:02PM
02:30PM
Aug-03-22 04:05PM
Jul-19-22 08:00AM
Jun-23-22 07:30AM
Jun-08-22 07:30AM
Jun-02-22 04:01PM
May-13-22 07:30AM
May-11-22 07:00AM
May-04-22 05:54PM
04:01PM
May-03-22 08:00AM
May-02-22 11:18AM
(Simply Wall St.) +13.36%
Apr-25-22 04:01PM
08:00AM
Apr-06-22 07:30AM
Mar-30-22 07:00AM
Mar-22-22 08:00AM
Mar-10-22 07:30AM
Mar-08-22 08:00AM
Feb-08-22 07:30AM
Jan-10-22 07:30AM
Jan-08-22 07:01AM
Jan-04-22 07:30AM
Dec-21-21 07:30AM
Nov-30-21 07:30AM
Nov-18-21 08:00AM
Nov-15-21 07:30AM
Nov-03-21 08:00AM
Cognition Therapeutics, Inc. is a clinical stage neuroscience company, which engages in developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. It offers the CT1812 which aims to restore the damaged cellular processes that drive diseases such as Alzheimer's disease, dry age-related macular degeneration, geographic atrophy, and other conditions. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano on August 21, 2007 and is headquartered in Purchase, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Ricciardi Lisa CEO & President Mar 14 '24 Buy 1.75 5,700 9,975 291,345 Mar 14 04:34 PM
Index -
P/E -
EPS (ttm) -1.47
Insider Own 26.51%
Shs Outstand 10.72M
Perf Week -4.49%
Market Cap 92.63M
Forward P/E -
EPS next Y -1.92
Insider Trans -19.65%
Shs Float 7.89M
Perf Month 69.12%
Income -15.96M
PEG -
EPS next Q -0.43
Inst Own 10.93%
Short Float 1.83%
Perf Quarter 116.17%
Sales 0.00M
P/S -
EPS this Y -35.15%
Inst Trans 0.92%
Short Ratio 0.56
Perf Half Y 129.39%
Book/sh 3.82
P/B 2.26
EPS next Y 3.61%
ROA -31.15%
Short Interest 0.14M
Perf Year 89.14%
Cash/sh 3.85
P/C 2.24
EPS next 5Y -
ROE -32.93%
52W Range 2.38 - 11.99
Perf YTD 101.52%
Dividend Est. -
P/FCF -
EPS past 5Y -39.81%
ROI -38.96%
52W High -28.07%
Beta 1.42
Dividend TTM -
Quick Ratio 16.18
Sales past 5Y 0.00%
Gross Margin -
52W Low 262.39%
ATR (14) 1.25
Dividend Ex-Date -
Current Ratio 16.18
EPS Y/Y TTM -12.02%
Oper. Margin 0.00%
RSI (14) 55.68
Volatility 15.24% 18.88%
Employees 21
Debt/Eq 0.01
Sales Y/Y TTM -
Profit Margin -
Recom 2.00
Target Price 20.50
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q -24.47%
Payout -
Rel Volume 1.10
Prev Close 9.78
Sales Surprise -
EPS Surprise 2.50%
Sales Q/Q -
Earnings Mar 18 AMC
Avg Volume 256.49K
Price 8.62
SMA20 13.98%
SMA50 56.42%
SMA200 90.88%
Trades
Volume 238,497
Change -11.81%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-07-21 Initiated
H.C. Wainwright
Buy
$32
Mar-20-24 09:00AM
Mar-19-24 09:06AM
Mar-18-24 08:53PM
05:32PM
04:02PM
08:00AM
Loading…
Mar-15-24 08:00AM
Mar-11-24 07:30AM
Mar-07-24 06:17AM
Mar-05-24 08:01AM
Mar-04-24 08:01AM
Feb-20-24 08:01AM
Feb-15-24 08:01AM
Jan-17-24 07:30AM
Dec-13-23 08:05AM
Nov-30-23 08:00AM
11:31AM
Loading…
Nov-10-23 11:31AM
Nov-08-23 06:43PM
04:01PM
Nov-01-23 08:00AM
Oct-24-23 04:03PM
Oct-10-23 08:00AM
Oct-03-23 08:00AM
Sep-29-23 07:40AM
Sep-25-23 08:30AM
Sep-18-23 09:00AM
Sep-14-23 09:09AM
Aug-31-23 08:00AM
Aug-28-23 05:32PM
08:00AM
Aug-23-23 06:00PM
08:30AM
Loading…
Aug-14-23 08:30AM
Aug-10-23 08:37AM
(Zacks Small Cap Research) +7.07%
Aug-09-23 04:01PM
09:11AM
Aug-08-23 03:06PM
Aug-02-23 12:45PM
08:00AM
Aug-01-23 07:30PM
Jul-30-23 02:45PM
Jul-17-23 08:00AM
Jun-26-23 08:30AM
Jun-12-23 08:30AM
Jun-08-23 09:00AM
May-19-23 06:50AM
May-17-23 08:00AM
May-10-23 09:59AM
(Zacks Small Cap Research)
May-09-23 04:01PM
May-03-23 09:00AM
May-02-23 04:01PM
07:30AM
Apr-13-23 07:30AM
Mar-28-23 08:00AM
Mar-24-23 07:15AM
Mar-22-23 11:50AM
11:45AM
(Zacks Small Cap Research)
Mar-21-23 04:01PM
12:11PM
(Thomson Reuters StreetEvents)
Mar-20-23 04:01PM
Mar-15-23 08:00AM
Mar-13-23 08:00AM
06:16AM
06:00AM
Mar-09-23 08:00AM
Mar-08-23 08:00AM
Mar-06-23 08:00AM
Mar-02-23 08:00AM
Feb-27-23 08:00AM
Feb-21-23 12:10PM
Feb-15-23 08:00AM
Feb-01-23 04:55AM
(Zacks Small Cap Research)
Jan-17-23 08:00AM
Jan-05-23 08:59AM
Dec-31-22 06:15AM
Dec-15-22 08:00AM
Dec-13-22 08:00AM
Dec-02-22 01:46PM
08:00AM
Nov-22-22 08:00AM
Nov-08-22 04:48AM
(Zacks Small Cap Research)
Nov-07-22 04:01PM
Nov-02-22 08:00AM
Oct-31-22 08:00AM
Oct-25-22 08:00AM
Oct-21-22 07:00AM
Oct-20-22 07:59AM
Oct-13-22 10:48AM
Oct-11-22 04:00PM
Oct-05-22 08:00AM
Sep-23-22 08:50AM
Sep-19-22 08:50AM
Sep-14-22 12:05PM
08:50AM
Aug-30-22 09:00AM
Aug-19-22 08:30AM
Aug-09-22 08:20AM
(Zacks Small Cap Research)
Aug-08-22 04:01PM
Aug-01-22 07:00AM
Jul-14-22 07:00AM
May-12-22 07:00AM
May-06-22 10:29AM
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Kreis Leslie W. 10% Owner Feb 29 '24 Sale 4.87 19,703 95,954 60,256 Feb 29 09:54 PM Fletcher Aaron G.L. 10% Owner Feb 29 '24 Sale 4.87 19,703 95,954 60,256 Feb 29 09:54 PM Fletcher Aaron G.L. 10% Owner Feb 28 '24 Sale 4.85 74,297 360,340 62,088 Feb 29 09:54 PM Kreis Leslie W. 10% Owner Feb 28 '24 Sale 4.85 74,297 360,340 62,088 Feb 29 09:54 PM Kreis Leslie W. 10% Owner Feb 27 '24 Sale 4.40 50,000 220,000 68,997 Feb 29 09:54 PM Fletcher Aaron G.L. 10% Owner Feb 27 '24 Sale 4.40 50,000 220,000 68,997 Feb 29 09:54 PM Kreis Leslie W. 10% Owner Jan 17 '24 Sale 4.20 58,889 247,334 73,646 Jan 19 04:30 PM Fletcher Aaron G.L. 10% Owner Jan 17 '24 Sale 4.20 58,889 247,334 73,646 Jan 19 04:31 PM Kreis Leslie W. 10% Owner Nov 29 '23 Sale 3.44 145,348 499,997 217,553 Dec 01 06:00 AM Fletcher Aaron G.L. 10% Owner Nov 29 '23 Sale 3.44 145,348 499,997 217,553 Dec 01 06:01 AM
Index -
P/E -
EPS (ttm) -1.01
Insider Own 32.38%
Shs Outstand 43.29M
Perf Week -4.00%
Market Cap 51.95M
Forward P/E -
EPS next Y -0.55
Insider Trans 0.00%
Shs Float 29.27M
Perf Month 4.35%
Income -30.01M
PEG -
EPS next Q -0.17
Inst Own 27.27%
Short Float 0.29%
Perf Quarter -15.49%
Sales 0.00M
P/S -
EPS this Y 35.50%
Inst Trans -22.50%
Short Ratio 0.49
Perf Half Y 11.11%
Book/sh 0.58
P/B 2.08
EPS next Y 14.73%
ROA -89.91%
Short Interest 0.08M
Perf Year -2.44%
Cash/sh 0.49
P/C 2.44
EPS next 5Y -
ROE -125.90%
52W Range 0.65 - 3.95
Perf YTD -13.04%
Dividend Est. -
P/FCF -
EPS past 5Y -50.62%
ROI -105.97%
52W High -69.62%
Beta -0.00
Dividend TTM -
Quick Ratio 4.57
Sales past 5Y 0.00%
Gross Margin -
52W Low 84.62%
ATR (14) 0.11
Dividend Ex-Date -
Current Ratio 4.57
EPS Y/Y TTM 25.79%
Oper. Margin 0.00%
RSI (14) 49.24
Volatility 8.46% 9.36%
Employees 31
Debt/Eq 0.20
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 8.62
Option/Short No / Yes
LT Debt/Eq 0.14
EPS Q/Q 33.21%
Payout -
Rel Volume 0.58
Prev Close 1.21
Sales Surprise -
EPS Surprise -43.51%
Sales Q/Q -
Earnings Mar 14 AMC
Avg Volume 174.60K
Price 1.20
SMA20 -1.11%
SMA50 -1.34%
SMA200 -3.35%
Trades
Volume 85,474
Change -0.83%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-18-24 Initiated
Laidlaw
Buy
$7.50
Aug-30-22 Initiated
H.C. Wainwright
Buy
$14
Mar-14-24 09:54PM
04:00PM
Mar-05-24 04:30PM
Feb-26-24 08:00AM
Feb-14-24 08:00AM
08:00AM
Loading…
Jan-04-24 08:00AM
Dec-11-23 04:05PM
09:00AM
Dec-07-23 08:00AM
Dec-05-23 08:00AM
Nov-20-23 07:00AM
Nov-10-23 07:00AM
Nov-09-23 04:00PM
Nov-06-23 08:00AM
Nov-03-23 12:00PM
09:17AM
Loading…
Nov-02-23 09:17AM
Nov-01-23 08:00AM
Oct-12-23 08:00AM
Sep-29-23 08:00AM
Sep-26-23 08:00AM
Sep-20-23 08:00AM
Sep-19-23 08:03AM
Sep-06-23 08:00AM
Aug-15-23 08:00AM
Aug-10-23 04:15PM
Aug-08-23 08:00AM
Jun-05-23 08:00AM
May-17-23 08:00AM
May-12-23 08:00AM
May-02-23 05:08PM
08:00AM
Loading…
May-01-23 08:00AM
Apr-26-23 10:00AM
Apr-25-23 08:00AM
Apr-24-23 08:00AM
Apr-17-23 09:00AM
Apr-11-23 08:00AM
Mar-30-23 04:15PM
Mar-16-23 08:00AM
Mar-01-23 08:00AM
Feb-23-23 07:00AM
Feb-21-23 07:00AM
Jan-17-23 07:00AM
Jan-05-23 07:00AM
Jan-03-23 07:00AM
Dec-12-22 07:00AM
Dec-08-22 07:00AM
Nov-10-22 07:30AM
Nov-03-22 09:10AM
Nov-01-22 07:30AM
Sep-27-22 07:30AM
Sep-15-22 07:30AM
Sep-13-22 07:30AM
Sep-08-22 07:30AM
Aug-30-22 04:15PM
Aug-19-22 09:20AM
Aug-16-22 04:15PM
Aug-12-22 04:15PM
Aug-11-22 10:05PM
Jul-27-22 07:00AM
Jul-21-22 07:00AM
Jul-12-22 08:00AM
Jul-10-22 09:12AM
Jun-30-22 04:15PM
Jun-08-22 08:00AM
Jun-06-22 07:00AM
May-17-22 07:00AM
May-12-22 08:00AM
May-05-22 08:00AM
May-04-22 08:00AM
May-03-22 11:00AM
(Simply Wall St.) +11.11%
Apr-13-22 08:30AM
Apr-05-22 04:15PM
Mar-28-22 08:00AM
Mar-17-22 04:15PM
Mar-04-22 07:00AM
Feb-10-22 05:36PM
Jan-31-22 12:29PM
(Simply Wall St.) +12.33%
Jan-10-22 07:00AM
Jan-06-22 07:00AM
Dec-16-21 07:00AM
Dec-09-21 04:30PM
Nov-16-21 07:00AM
Nov-11-21 07:00AM
Nov-10-21 04:15PM
Nov-04-21 08:00AM
Nov-01-21 09:28AM
Oct-27-21 07:00AM
Oct-04-21 04:15PM
Sep-10-21 04:15PM
Aug-30-21 07:00AM
Aug-11-21 08:00AM
Aug-04-21 08:00AM
Jul-30-21 07:00AM
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Graff Jeremy R. Director Sep 13 '23 Buy 0.95 2,500 2,375 2,500 Sep 15 04:51 PM McCall Patrick Chief Financial Officer Aug 25 '23 Buy 1.03 1,000 1,030 6,263 Aug 28 04:43 PM Ho William Tai-Wei President and CEO Aug 24 '23 Buy 1.05 23,800 24,990 2,339,545 Aug 28 04:42 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite